{"ticker": {"uuid": "82692a53-c917-4dae-b951-8d2705bd4cf1", "symbol": "NEUP", "name": "Neuphoria Therapeutics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Number of shareholders of Neuphoria Therapeutics Inc. \u2013 NASDAQ:NEUP", "summary": "This article provides details on the number of shareholders for Neuphoria Therapeutics Inc. (NASDAQ: NEUP). It indicates that the information is presented by period, value, change, and change percentage, with data sourced from FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-11T02:39:19", "published_display": "11 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP - Neuphoria Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Neuphoria Therapeutics Inc. It includes detailed information on the company's market performance, key financial ratios, insider and institutional ownership, and stock performance metrics. The data c", "url": "https://finviz.com/stock?t=NEUP&ta=1&p=w&ty=lf&page=6", "source_name": "Finviz", "published_at": "2026-07-04T16:41:59", "published_display": "04 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer\u2019s Drug Trial Under Neuphoria Partnership", "summary": "Merck (MRK) shares dropped over 2% and Neuphoria Therapeutics (NEUP) fell 19% after Merck terminated a mid-stage trial for its Alzheimer's drug, MK-1167, citing business reasons due to insufficient performance. This marks a second discontinuation for a drug developed under their ", "url": "https://stocktwits.com/news-articles/markets/equity/mrk-neup-stocks-drop-as-merck-scraps-another-alzheimers-drug-under-neuphoria-partnership/cZm3ANLR711", "source_name": "Stocktwits", "published_at": "2026-07-01T18:01:00", "published_display": "01 Jul 2026 18:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck halts ph. 2 Alzheimer\u2019s trial after Neuphoria small molecule underwhelms", "summary": "Merck has discontinued a phase 2 study for its Alzheimer's disease candidate, MK-1167, due to underwhelming efficacy in an interim analysis. This marks another setback for Merck's partner, Neuphoria Therapeutics, which recently faced a failed phase 3 trial for a social anxiety ca", "url": "https://www.fiercebiotech.com/biotech/merck-halts-ph-2-alzheimers-trial-after-neuphoria-small-molecule-underwhelms", "source_name": "Fierce Biotech", "published_at": "2026-07-01T14:35:00", "published_display": "01 Jul 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria confirms merger talks with Scancell Holdings", "summary": "Neuphoria Therapeutics Inc. confirmed it is in discussions with Scancell Holdings plc regarding a potential acquisition, which would make Scancell a Nasdaq-listed company. The discussions follow speculation in the UK press and come after Neuphoria's lead drug candidate, BNC210, f", "url": "https://www.investing.com/news/company-news/neuphoria-confirms-merger-talks-with-scancell-holdings-93CH-4763451", "source_name": "Investing.com", "published_at": "2026-06-30T17:42:09", "published_display": "30 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc", "summary": "Neuphoria Therapeutics Inc. has confirmed it is in discussions with London-listed Scancell Holdings plc regarding a potential acquisition. The talks were prompted by speculation in the UK press and an announcement from Scancell. While discussions are ongoing, Neuphoria emphasizes", "url": "https://uk.finance.yahoo.com/news/neuphoria-responds-announcement-made-london-201500682.html", "source_name": "Market source", "published_at": "2026-06-28T16:42:00", "published_display": "28 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc's stock price recorded a significant increase of 6% in after-hours trading, closing at $4.85.", "summary": "Neuphoria Therapeutics Inc.'s stock price rose by 6% in after-hours trading to $4.85, amidst light trading volume. The company confirmed it is in acquisition talks with biopharmaceutical company Scancell, which directly influenced the stock's performance.", "url": "https://www.bitget.com/asia/news/detail/12560605479552", "source_name": "Bitget", "published_at": "2026-06-27T16:39:20", "published_display": "27 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Confirms Business Combination Talks With Scancell", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neuphoria-confirms-business-combination-talks-203624133.html", "source_name": "MT Newswires", "published_at": "2026-06-26T20:36:24+00:00", "published_display": "26 Jun 2026 20:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell", "summary": "Neuphoria Therapeutics has confirmed it is in discussions regarding a potential acquisition by Scancell. The brief report, sourced from Reuters via Refinitiv, indicates that further details were not immediately available beyond the confirmation of these talks.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Y163:0-neuphoria-therapeutics-confirms-discussions-on-potential-acquisition-by-scancell/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:17", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP)", "summary": "This article provides an overview of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) stock, including its current price, market capitalization, and historical performance. It details financial estimates, such as earnings per share and revenue, and notes that the company does not pay d", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:17", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scancell confirms advanced talks over reverse merger with Neuphoria", "summary": "Scancell Holdings PLC, a developer of cancer immunotherapies, has confirmed it is in advanced discussions for a reverse merger with US-listed Neuphoria Therapeutics. The all-share transaction could provide Scancell with a Nasdaq listing, enhancing its profile among US investors. ", "url": "https://finance.yahoo.com/healthcare/articles/scancell-confirms-advanced-talks-over-134500374.html", "source_name": "Market source", "published_at": "2026-06-26T14:09:29", "published_display": "26 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Neuphoria Therapeutics Inc. (NEUP) stock, including its current price, market capitalization, and historical performance. It details recent earnings and revenue figures, upcoming earnings dates, and general advice on investing in NEUP stock. T", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:29", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scancell in talks for reverse merger with Neuphoria Therapeutics", "summary": "Scancell Holdings plc is in advanced discussions for a potential reverse merger with Neuphoria Therapeutics Inc., an all-share transaction aimed at facilitating a Nasdaq listing for Scancell. This move would enhance Scancell's profile with U.S. investors and includes plans for eq", "url": "https://www.investing.com/news/company-news/scancell-in-talks-for-reverse-merger-with-neuphoria-therapeutics-93CH-4762881", "source_name": "Investing.com", "published_at": "2026-06-26T14:09:17", "published_display": "26 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Neuphoria Therapeutics Inc (NEUP), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently ranks low in the Biotechnology & Medi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/technical", "source_name": "TradingKey", "published_at": "2026-06-24T12:40:59", "published_display": "24 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Neuphoria Therapeutics Inc (NEUP), listing major shareholders and their recent activity. It shows various institutional investors, their shareholdings, and the percentage change in their positions, highlighting sign", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:27", "published_display": "18 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Neuphoria Therapeutics Inc (NEUP) stock information, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T15:39:44", "published_display": "18 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Neuphoria Therapeutics Inc (NEUP), covering business segments and regional contributions. As of March 4, 2025, the company has not disclosed relevant data for FY2019 and FY2020. The only regional revenue reported is from Australia, am", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:39:44", "published_display": "18 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Neuphoria Therapeutics Inc (NEUP), noting its current valuation score of 8.32 and its ranking within the Biotechnology & Medical Research industry. It highlights the stock's P/E ratio and mentions that relevant data for P/B, P/S, and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:10", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Neuphoria Therapeutics Inc (NEUP) has an earnings forecast score of 8.00 and an average price target of $20.00, according to analyst ratings. One analyst has a \"Hold\" rating for the stock, with a target price indicating a 63.55% upside. The company's EPS for the previous quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:10", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings", "summary": "This article provides an overview of Neuphoria Therapeutics Inc.'s SEC filings and other key documents, detailing the company's financial performance, operational updates, and clinical trial progress for its NEUP stock. It highlights significant events such as the pausing of R&D,", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/documents/", "source_name": "TradingView", "published_at": "2026-06-10T06:39:30", "published_display": "10 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Registration filing Summary", "summary": "Neuphoria Therapeutics (NEUP) has filed a registration summary detailing its business as a clinical-stage biopharmaceutical company focused on CNS disorders. The company's lead candidate, BNC210, targets PTSD and SAD, and it has a strategic partnership with Merck. The filing also", "url": "https://quartr.com/events/neuphoria-therapeutics-neup-registration-filing_F16Zjvmh", "source_name": "Quartr", "published_at": "2026-06-08T23:11:12", "published_display": "08 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP - Neuphoria Therapeutics Inc Stock Price and Quote", "summary": "This page provides detailed stock information for Neuphoria Therapeutics Inc. (NEUP), including its last close price, financial metrics, analyst ratings, and a chronological list of company news and press releases. Key recent events include discussions regarding a potential rever", "url": "https://finviz.com/stock?t=NEUP", "source_name": "Finviz", "published_at": "2026-06-01T03:09:33", "published_display": "01 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial", "summary": "Neuphoria Therapeutics (NEUP) recently received an AUD $1.416 million milestone payment from Pfizer related to the KAT6 program, triggered by the first dosing in a Phase III trial for metastatic breast cancer. This payment contributes to the AUD $3.52 million Neuphoria has receiv", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NEUP/pressreleases/2162541/neuphoria-receives-milestone-revenue-from-pfizer-kat6-trial/", "source_name": "The Globe and Mail", "published_at": "2026-05-26T11:39:27", "published_display": "26 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Holds Steady Near Support \u2013 Can the Range Hold? - Up Down Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWWNoai1EaEZ2Wkk1dy16NVRwZjQwOWtCcElwU0V1dXZvbzRpbWtZU1NmM2VrbVliQ09BajJnSHJ3QzBlVXdmekpwNUQ1WkM1NEZ0ZU4yeDFZUVl1WXNjY0s5WU5pN1d3WW5fbG56OEVJRXR1ZzhyMHhuMEdNUjZZNmxIQjZ4MVl5N2RZZEtVNXZ3VnRrVHo2ajljUTRabmJ5Wmw2TElrMUo4bmRhNGVtY25EdjVWd29qeThR?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish Breakout - McClellan Oscillator", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOQmh3RXFBeWI1V3NjWU84YkF4bmRPVGN4NVE2OGNrbkN4MU9zYjNDUE9rdU85NkV2ZW12WEJWRFBZMzFpZWlYbnhDUm5zVi1QN3MzaTNUd1dOUVYtYW8wd2paMlBmdHpsSXg1bmhyWWtqY1pFcmtwenN2WDNSWm9lRjNGbDFlZ3pyQXYyVDZyUndnczZ3T0JaUy15VHJZenNFemw0MjVkSk52Rl9zVnZOMHlEbGF1c2VNODJIZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Neuphoria Therapeutics(NEUP.US) With Hold Rating", "summary": "This article states that H.C. Wainwright has maintained its Hold rating on Neuphoria Therapeutics (NEUP.US). No additional details or analysis are provided in the current document.", "url": "https://www.moomoo.com/news/post/70185620/hc-wainwright-maintains-neuphoria-therapeutics-neupus-with-hold-rating", "source_name": "Moomoo", "published_at": "2026-05-18T01:39:59", "published_display": "18 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026", "summary": "Neuphoria Therapeutics Inc. has reported its financial results for the third quarter and nine months ended March 31, 2026. The company posted a net loss of USD 0.505063 million for the third quarter, a significant decline from a net income of USD 11.26 million in the prior year. ", "url": "https://www.marketscreener.com/news/neuphoria-therapeutics-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-mar-ce7f5bd3df81f424", "source_name": "www.marketscreener.com", "published_at": "2026-05-16T07:40:38", "published_display": "16 May 2026 07:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Downgrades Neuphoria Therapeutics(NEUP.US) to Hold Rating", "summary": "H.C. Wainwright has downgraded Neuphoria Therapeutics (NEUP.US) to a Hold rating. No further details about the reasons for the downgrade were provided in this brief announcement.", "url": "https://www.moomoo.com/news/post/70111542/hc-wainwright-downgrades-neuphoria-therapeutics-neupus-to-hold-rating", "source_name": "Moomoo", "published_at": "2026-05-15T21:09:57", "published_display": "15 May 2026 21:09", "sentiment": "negative", "sentiment_pct": 32, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc expected to post a loss of $1.12 a share - Earnings Preview", "summary": "Neuphoria Therapeutics Inc. is projected to report an earnings loss of $1.12 per share. This information comes from an earnings preview provided by Refinitiv. The article provides no additional details beyond this forecasted loss.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41S23I:0-neuphoria-therapeutics-inc-expected-to-post-a-loss-of-1-12-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-15T20:10:54", "published_display": "15 May 2026 20:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNRnBrdGJUWndHNk5SRUM3eVlWYnp4NTdINnVjNDJSMXRnZ3BENXVaUWdwSXJNSklGWExzZjRrLWVHU3RCV241NlJkalZHdW1DX3kxcTA3SlF6dXpBcFp0Mm52ME4tam9wbGtzX0tKbUxOQld5dzhZeENyNlYzQ3RuQ3RjaDVwMWVLemhmTU1FSXBBREt4enJJ?oc=5", "source_name": "Market source", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9oNTVXRFlsbXI1c3RsWTRjaWR3MU45OTNWRlJWa1ZZUkJaY2swaldxdmxxX05KTU5HSXYxYkFabkhrLW8xTTM2b3ZFeG1UcUQxUVNZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-26T01:10:15+00:00", "published_display": "26 Apr 2025 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. (NEUP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9VY002YTFFUFp1dklKSHlyMW95X0pBOEYyUHBFd3NfazZtRUtRVHdZQjNFZVQ2ODZQcHBqOWkydTQ4ZEFrZ2owQVg5aWx3dGc?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-12-26T20:11:57+00:00", "published_display": "26 Dec 2024 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP Stock Price and Chart \u2014 NASDAQ:NEUP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9BdlZ2alphaXpYSEN2dnY3NjNjRllPQ1lmVE1oSlhDZnRyeVlXWFliWmZZbDhJMWQxS1EyMHl6SFBOeHdfdXE3dmhfNEp2R0F2LXZyTzQ2ZExPYkZH?oc=5", "source_name": "TradingView", "published_at": "2024-12-24T15:22:57+00:00", "published_display": "24 Dec 2024 15:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Completes Scheme of Arrangement for Bionomics Limited's Re-Domiciliation to the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQOW42VW0xbEtZbGhOY1ZhaG12QzQ5RFlVZFpONURyNUdKeDZKUzRYOE82VDlWcy1VYmd6cWhFX1JtdndGM1JmQjF5VDZTR3RKVG9iaEtvOFdvX0hsUDRZeF9XampJY1hQN2VxTlNYOTgwOHhrUUlnY2VUaUsxeFJISHZ1ZlRueEhENkRKeTVtMzhaamRDODNaQkpfWGhFTE5fSURnQ3dHVGpzSEJ1WmkxcU5EVVhKdkRaaXU0ZlBOZFRfcUhMZkRheTBMU3ZRYVpQRDYySlItNUd3NnBnMHpZcA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-23T08:00:00+00:00", "published_display": "23 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Number of shareholders of Neuphoria Therapeutics Inc. \u2013 NASDAQ:NEUP", "summary": "This article provides details on the number of shareholders for Neuphoria Therapeutics Inc. (NASDAQ: NEUP). It indicates that the information is presented by period, value, change, and change percentage, with data sourced from FactSet Research Systems Inc.", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/financials-statistics-and-ratios/number-of-shareholders/", "source_name": "TradingView", "published_at": "2026-07-11T02:39:19", "published_display": "11 Jul 2026 02:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP - Neuphoria Therapeutics Inc Latest SEC Filings", "summary": "This article provides the latest SEC filings and comprehensive financial data for Neuphoria Therapeutics Inc. It includes detailed information on the company's market performance, key financial ratios, insider and institutional ownership, and stock performance metrics. The data c", "url": "https://finviz.com/stock?t=NEUP&ta=1&p=w&ty=lf&page=6", "source_name": "Finviz", "published_at": "2026-07-04T16:41:59", "published_display": "04 Jul 2026 16:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "MRK, NEUP Stocks Drop As Merck Scraps Another Alzheimer\u2019s Drug Trial Under Neuphoria Partnership", "summary": "Merck (MRK) shares dropped over 2% and Neuphoria Therapeutics (NEUP) fell 19% after Merck terminated a mid-stage trial for its Alzheimer's drug, MK-1167, citing business reasons due to insufficient performance. This marks a second discontinuation for a drug developed under their ", "url": "https://stocktwits.com/news-articles/markets/equity/mrk-neup-stocks-drop-as-merck-scraps-another-alzheimers-drug-under-neuphoria-partnership/cZm3ANLR711", "source_name": "Stocktwits", "published_at": "2026-07-01T18:01:00", "published_display": "01 Jul 2026 18:01", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Merck halts ph. 2 Alzheimer\u2019s trial after Neuphoria small molecule underwhelms", "summary": "Merck has discontinued a phase 2 study for its Alzheimer's disease candidate, MK-1167, due to underwhelming efficacy in an interim analysis. This marks another setback for Merck's partner, Neuphoria Therapeutics, which recently faced a failed phase 3 trial for a social anxiety ca", "url": "https://www.fiercebiotech.com/biotech/merck-halts-ph-2-alzheimers-trial-after-neuphoria-small-molecule-underwhelms", "source_name": "Fierce Biotech", "published_at": "2026-07-01T14:35:00", "published_display": "01 Jul 2026 14:35", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria confirms merger talks with Scancell Holdings", "summary": "Neuphoria Therapeutics Inc. confirmed it is in discussions with Scancell Holdings plc regarding a potential acquisition, which would make Scancell a Nasdaq-listed company. The discussions follow speculation in the UK press and come after Neuphoria's lead drug candidate, BNC210, f", "url": "https://www.investing.com/news/company-news/neuphoria-confirms-merger-talks-with-scancell-holdings-93CH-4763451", "source_name": "Investing.com", "published_at": "2026-06-30T17:42:09", "published_display": "30 Jun 2026 17:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 96, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc", "summary": "Neuphoria Therapeutics Inc. has confirmed it is in discussions with London-listed Scancell Holdings plc regarding a potential acquisition. The talks were prompted by speculation in the UK press and an announcement from Scancell. While discussions are ongoing, Neuphoria emphasizes", "url": "https://uk.finance.yahoo.com/news/neuphoria-responds-announcement-made-london-201500682.html", "source_name": "Market source", "published_at": "2026-06-28T16:42:00", "published_display": "28 Jun 2026 16:42", "sentiment": "positive", "sentiment_pct": 60, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc's stock price recorded a significant increase of 6% in after-hours trading, closing at $4.85.", "summary": "Neuphoria Therapeutics Inc.'s stock price rose by 6% in after-hours trading to $4.85, amidst light trading volume. The company confirmed it is in acquisition talks with biopharmaceutical company Scancell, which directly influenced the stock's performance.", "url": "https://www.bitget.com/asia/news/detail/12560605479552", "source_name": "Bitget", "published_at": "2026-06-27T16:39:20", "published_display": "27 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Confirms Business Combination Talks With Scancell", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/neuphoria-confirms-business-combination-talks-203624133.html", "source_name": "MT Newswires", "published_at": "2026-06-26T20:36:24+00:00", "published_display": "26 Jun 2026 20:36", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Confirms Discussions On Potential Acquisition By Scancell", "summary": "Neuphoria Therapeutics has confirmed it is in discussions regarding a potential acquisition by Scancell. The brief report, sourced from Reuters via Refinitiv, indicates that further details were not immediately available beyond the confirmation of these talks.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_FWN42Y163:0-neuphoria-therapeutics-confirms-discussions-on-potential-acquisition-by-scancell/", "source_name": "TradingView", "published_at": "2026-06-26T21:09:17", "published_display": "26 Jun 2026 21:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Actuals & Estimates (NASDAQ:NEUP)", "summary": "This article provides an overview of Neuphoria Therapeutics Inc. (NASDAQ: NEUP) stock, including its current price, market capitalization, and historical performance. It details financial estimates, such as earnings per share and revenue, and notes that the company does not pay d", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T20:09:17", "published_display": "26 Jun 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scancell confirms advanced talks over reverse merger with Neuphoria", "summary": "Scancell Holdings PLC, a developer of cancer immunotherapies, has confirmed it is in advanced discussions for a reverse merger with US-listed Neuphoria Therapeutics. The all-share transaction could provide Scancell with a Nasdaq listing, enhancing its profile among US investors. ", "url": "https://finance.yahoo.com/healthcare/articles/scancell-confirms-advanced-talks-over-134500374.html", "source_name": "Market source", "published_at": "2026-06-26T14:09:29", "published_display": "26 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides an overview of Neuphoria Therapeutics Inc. (NEUP) stock, including its current price, market capitalization, and historical performance. It details recent earnings and revenue figures, upcoming earnings dates, and general advice on investing in NEUP stock. T", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T14:09:29", "published_display": "26 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Scancell in talks for reverse merger with Neuphoria Therapeutics", "summary": "Scancell Holdings plc is in advanced discussions for a potential reverse merger with Neuphoria Therapeutics Inc., an all-share transaction aimed at facilitating a Nasdaq listing for Scancell. This move would enhance Scancell's profile with U.S. investors and includes plans for eq", "url": "https://www.investing.com/news/company-news/scancell-in-talks-for-reverse-merger-with-neuphoria-therapeutics-93CH-4762881", "source_name": "Investing.com", "published_at": "2026-06-26T14:09:17", "published_display": "26 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 64, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Neuphoria Therapeutics Inc (NEUP), detailing its current price momentum score, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently ranks low in the Biotechnology & Medi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/technical", "source_name": "TradingKey", "published_at": "2026-06-24T12:40:59", "published_display": "24 Jun 2026 12:40", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Institutional Confidence", "summary": "This article provides details on the institutional confidence in Neuphoria Therapeutics Inc (NEUP), listing major shareholders and their recent activity. It shows various institutional investors, their shareholdings, and the percentage change in their positions, highlighting sign", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T22:09:27", "published_display": "18 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Neuphoria Therapeutics Inc (NEUP) stock information, focusing on its dividend and stock split history. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split data. The current stock", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T15:39:44", "published_display": "18 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a revenue breakdown for Neuphoria Therapeutics Inc (NEUP), covering business segments and regional contributions. As of March 4, 2025, the company has not disclosed relevant data for FY2019 and FY2020. The only regional revenue reported is from Australia, am", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:39:44", "published_display": "18 Jun 2026 11:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Neuphoria Therapeutics Inc (NEUP), noting its current valuation score of 8.32 and its ranking within the Biotechnology & Medical Research industry. It highlights the stock's P/E ratio and mentions that relevant data for P/B, P/S, and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T05:39:10", "published_display": "18 Jun 2026 05:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc (NEUP) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "Neuphoria Therapeutics Inc (NEUP) has an earnings forecast score of 8.00 and an average price target of $20.00, according to analyst ratings. One analyst has a \"Hold\" rating for the stock, with a target price indicating a 63.55% upside. The company's EPS for the previous quarter ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-neup/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T01:39:10", "published_display": "18 Jun 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Financial Disclosures & SEC Filings", "summary": "This article provides an overview of Neuphoria Therapeutics Inc.'s SEC filings and other key documents, detailing the company's financial performance, operational updates, and clinical trial progress for its NEUP stock. It highlights significant events such as the pausing of R&D,", "url": "https://www.tradingview.com/symbols/NASDAQ-NEUP/documents/", "source_name": "TradingView", "published_at": "2026-06-10T06:39:30", "published_display": "10 Jun 2026 06:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Registration filing Summary", "summary": "Neuphoria Therapeutics (NEUP) has filed a registration summary detailing its business as a clinical-stage biopharmaceutical company focused on CNS disorders. The company's lead candidate, BNC210, targets PTSD and SAD, and it has a strategic partnership with Merck. The filing also", "url": "https://quartr.com/events/neuphoria-therapeutics-neup-registration-filing_F16Zjvmh", "source_name": "Quartr", "published_at": "2026-06-08T23:11:12", "published_display": "08 Jun 2026 23:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're A Bit Worried About Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP - Neuphoria Therapeutics Inc Stock Price and Quote", "summary": "This page provides detailed stock information for Neuphoria Therapeutics Inc. (NEUP), including its last close price, financial metrics, analyst ratings, and a chronological list of company news and press releases. Key recent events include discussions regarding a potential rever", "url": "https://finviz.com/stock?t=NEUP", "source_name": "Finviz", "published_at": "2026-06-01T03:09:33", "published_display": "01 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Receives Milestone Revenue From Pfizer KAT6 Trial", "summary": "Neuphoria Therapeutics (NEUP) recently received an AUD $1.416 million milestone payment from Pfizer related to the KAT6 program, triggered by the first dosing in a Phase III trial for metastatic breast cancer. This payment contributes to the AUD $3.52 million Neuphoria has receiv", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NEUP/pressreleases/2162541/neuphoria-receives-milestone-revenue-from-pfizer-kat6-trial/", "source_name": "The Globe and Mail", "published_at": "2026-05-26T11:39:27", "published_display": "26 May 2026 11:39", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Holds Steady Near Support \u2013 Can the Range Hold? - Up Down Volume", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxNWWNoai1EaEZ2Wkk1dy16NVRwZjQwOWtCcElwU0V1dXZvbzRpbWtZU1NmM2VrbVliQ09BajJnSHJ3QzBlVXdmekpwNUQ1WkM1NEZ0ZU4yeDFZUVl1WXNjY0s5WU5pN1d3WW5fbG56OEVJRXR1ZzhyMHhuMEdNUjZZNmxIQjZ4MVl5N2RZZEtVNXZ3VnRrVHo2ajljUTRabmJ5Wmw2TElrMUo4bmRhNGVtY25EdjVWd29qeThR?oc=5", "source_name": "Donan\u0131mHaber", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Soars 7%: Key Levels to Watch After Bullish Breakout - McClellan Oscillator", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxOQmh3RXFBeWI1V3NjWU84YkF4bmRPVGN4NVE2OGNrbkN4MU9zYjNDUE9rdU85NkV2ZW12WEJWRFBZMzFpZWlYbnhDUm5zVi1QN3MzaTNUd1dOUVYtYW8wd2paMlBmdHpsSXg1bmhyWWtqY1pFcmtwenN2WDNSWm9lRjNGbDFlZ3pyQXYyVDZyUndnczZ3T0JaUy15VHJZenNFemw0MjVkSk52Rl9zVnZOMHlEbGF1c2VNODJIZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-05-25T07:00:00+00:00", "published_display": "25 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Maintains Neuphoria Therapeutics(NEUP.US) With Hold Rating", "summary": "This article states that H.C. Wainwright has maintained its Hold rating on Neuphoria Therapeutics (NEUP.US). No additional details or analysis are provided in the current document.", "url": "https://www.moomoo.com/news/post/70185620/hc-wainwright-maintains-neuphoria-therapeutics-neupus-with-hold-rating", "source_name": "Moomoo", "published_at": "2026-05-18T01:39:59", "published_display": "18 May 2026 01:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026", "summary": "Neuphoria Therapeutics Inc. has reported its financial results for the third quarter and nine months ended March 31, 2026. The company posted a net loss of USD 0.505063 million for the third quarter, a significant decline from a net income of USD 11.26 million in the prior year. ", "url": "https://www.marketscreener.com/news/neuphoria-therapeutics-inc-reports-earnings-results-for-the-third-quarter-and-nine-months-ended-mar-ce7f5bd3df81f424", "source_name": "www.marketscreener.com", "published_at": "2026-05-16T07:40:38", "published_display": "16 May 2026 07:40", "sentiment": "negative", "sentiment_pct": 30, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Downgrades Neuphoria Therapeutics(NEUP.US) to Hold Rating", "summary": "H.C. Wainwright has downgraded Neuphoria Therapeutics (NEUP.US) to a Hold rating. No further details about the reasons for the downgrade were provided in this brief announcement.", "url": "https://www.moomoo.com/news/post/70111542/hc-wainwright-downgrades-neuphoria-therapeutics-neupus-to-hold-rating", "source_name": "Moomoo", "published_at": "2026-05-15T21:09:57", "published_display": "15 May 2026 21:09", "sentiment": "negative", "sentiment_pct": 32, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc expected to post a loss of $1.12 a share - Earnings Preview", "summary": "Neuphoria Therapeutics Inc. is projected to report an earnings loss of $1.12 per share. This information comes from an earnings preview provided by Refinitiv. The article provides no additional details beyond this forecasted loss.", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41S23I:0-neuphoria-therapeutics-inc-expected-to-post-a-loss-of-1-12-a-share-earnings-preview/", "source_name": "TradingView", "published_at": "2026-05-15T20:10:54", "published_display": "15 May 2026 20:10", "sentiment": "negative", "sentiment_pct": 32, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Adopts Limited-Duration Stockholder Rights Plan to Protect Integrity of Process", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxNRnBrdGJUWndHNk5SRUM3eVlWYnp4NTdINnVjNDJSMXRnZ3BENXVaUWdwSXJNSklGWExzZjRrLWVHU3RCV241NlJkalZHdW1DX3kxcTA3SlF6dXpBcFp0Mm52ME4tam9wbGtzX0tKbUxOQld5dzhZeENyNlYzQ3RuQ3RjaDVwMWVLemhmTU1FSXBBREt4enJJ?oc=5", "source_name": "Market source", "published_at": "2025-10-27T07:00:00+00:00", "published_display": "27 Oct 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9oNTVXRFlsbXI1c3RsWTRjaWR3MU45OTNWRlJWa1ZZUkJaY2swaldxdmxxX05KTU5HSXYxYkFabkhrLW8xTTM2b3ZFeG1UcUQxUVNZ?oc=5", "source_name": "Stock Titan", "published_at": "2025-04-26T01:10:15+00:00", "published_display": "26 Apr 2025 01:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. (NEUP)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiT0FVX3lxTE9VY002YTFFUFp1dklKSHlyMW95X0pBOEYyUHBFd3NfazZtRUtRVHdZQjNFZVQ2ODZQcHBqOWkydTQ4ZEFrZ2owQVg5aWx3dGc?oc=5", "source_name": "Zacks Investment Research", "published_at": "2024-12-26T20:11:57+00:00", "published_display": "26 Dec 2024 20:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "NEUP Stock Price and Chart \u2014 NASDAQ:NEUP", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE9BdlZ2alphaXpYSEN2dnY3NjNjRllPQ1lmVE1oSlhDZnRyeVlXWFliWmZZbDhJMWQxS1EyMHl6SFBOeHdfdXE3dmhfNEp2R0F2LXZyTzQ2ZExPYkZH?oc=5", "source_name": "TradingView", "published_at": "2024-12-24T15:22:57+00:00", "published_display": "24 Dec 2024 15:22", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Neuphoria Therapeutics Inc. Completes Scheme of Arrangement for Bionomics Limited's Re-Domiciliation to the U.S.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi4AFBVV95cUxQOW42VW0xbEtZbGhOY1ZhaG12QzQ5RFlVZFpONURyNUdKeDZKUzRYOE82VDlWcy1VYmd6cWhFX1JtdndGM1JmQjF5VDZTR3RKVG9iaEtvOFdvX0hsUDRZeF9XampJY1hQN2VxTlNYOTgwOHhrUUlnY2VUaUsxeFJISHZ1ZlRueEhENkRKeTVtMzhaamRDODNaQkpfWGhFTE5fSURnQ3dHVGpzSEJ1WmkxcU5EVVhKdkRaaXU0ZlBOZFRfcUhMZkRheTBMU3ZRYVpQRDYySlItNUd3NnBnMHpZcA?oc=5", "source_name": "Quiver Quantitative", "published_at": "2024-12-23T08:00:00+00:00", "published_display": "23 Dec 2024 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxQcjZqdzdBcURDdWxCZUtoU1dTaHYtVUFRdlo1a3ZGZGY3a1dBX2x2UVE3Y1hoX1duLXhGU2p0UXU2eTctNng5eFJ5c1M0bHBNQ0VmZTFZanhYU21yTVo0UTQtVENveVV1aWdpc3luUlgza3AyUEI2OGx4aEhXc0pBTHpWUThSYXI1S3RTS21lQ21vWjd6MGY4ZDRwVWlEakc3SmFKN09aM0Rlb2pFT3BNNW1GTExnSElFb2NqR3JhX0J3MlptQy1mMk9IOTZtdS1HU25fLU9aOU9XZi1PRDlkZVI2cnhackHSAewBQVVfeXFMTlc2N3pIUkxDd1NtTlVRMEdac1JNSDF3cUNidkZrTElQREZaUTZjZmFHdUVWYW8wcDg1LThGbnlPb0VQUFI4ZXdjSXR6Ym5DREM1X2lyQUtYTzF3XzBBTGRGcEZQQ3FjLWxCQ0locVM2dGZJR1kxYmlBQXdsbFhfbFFISS1wSUkxQmp4U2d2Z3JHbXRPMUpnajBydTRmNnQzZmF5eEdzOVFRNUdDNVV0aDJQNERCaXN3ZGo1UUc1ZGkwOFYzcDgxS1ltZllDeTFxNFIxT3FyOUxLMFNrLUhtOFNFV0xMYkM5TlpWMzk?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5wFBVV95cUxOWWM3V1pmZzdlY1llRTljQmNLQ2UwdDdQaFVEcng2WVdrNE9qNzRrNVpBVlJNMGltQUhBUG1qellCVHNiM09fUkFHRW1kMEpvazJoLU11N3c4YnlWUXpmVl82aWNKeTA4U1RwSHNNSVd4d0lwWHRJclQ2TGNHWUpBQTgzbTBMVk05VGxYN0RwcmpTYklOQUFSWDhsSHZlQVpndmlPRGNvTmRmeHNILWg4ZE5jMjRoN01XNENiaVU2UDUyOWJfYUZCTm5URmtwTHJsTjJYNHo3RkxsQjBSMnBmdVZVWkFwN2PSAewBQVVfeXFMT3htM016bEt0TTdyOXE2amppMGpubTNfOFU4cGpxd2dFZkJDTjR3c0ZqOHpHYWZoamNLdmkxVmNYNklxTEM4NTU0bDZwUTZ1SW5Jc1c4NmRJN3lKQUVqUUNYYWptd2ZYNE9TeEhMRzFvbEt0bjk1TVhyVG44UnJnNDllTlFsalJVUTZwcEEzWXljbzdaQXdWWDlHQW56bGxqeG90UlFmaFFLekJlUlNIOVE4SGNHcE9pOW1KSllleVdwNERiaVl2NmxtNTNyaUtnSFY1VHUzcDJsWE9xb3R1ajZ2RGhkXzJzTldMOVA?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 88, "total_relevant": 43, "sentiment_summary": {"positive": 9, "negative": 6, "neutral": 28, "score": 51, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 73, "events": [{"event": "general", "label": "Market update", "weight": 8.6, "count": 15}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 15}, {"event": "deals", "label": "Deals and strategy", "weight": 4.4, "count": 8}, {"event": "analyst", "label": "Analyst action", "weight": 1.65, "count": 3}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 9, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 3.54, "latest_week": "2026-07-10", "one_week_move": 4.7, "four_week_move": -19.0, "twelve_week_move": -25.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.045654, "market_dynamics_buy_signal": false, "relative_strength": -52.603958, "fair_value_gap": -40.5, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "undecided", "expectation_probability": 52.0325, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.7% over one week, -19.0% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 57, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "TradingKey", "count": 6}, {"label": "simplywall.st", "count": 3}, {"label": "Finviz", "count": 2}, {"label": "Investing.com", "count": 2}, {"label": "Moomoo", "count": 2}, {"label": "Stocktwits", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 35}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 15}, {"label": "Market update", "count": 15}, {"label": "Deals and strategy", "count": 8}, {"label": "Analyst action", "count": 3}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "51/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "73/100 classification confidence."}, {"label": "Company focus", "value": "35", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.7% over one week, -19.0% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Number of shareholders of Neuphoria Therapeutics Inc. \u2013 NASDAQ:NEUP"}], "updated_at": "2026-07-16T02:16:46.614622+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}